|
93 Companies |
|
118 Products |
|
118 Products |
|
88 Mechanisms of Action |
|
3 Trials |
|
1622 News |
|
| «12...7891011121314151617...3233» |
- aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Nov 25, 2014
P2, N=22, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Mar 2015 --> Sep 2015
- ||||| New P4 trial: Improving Multivitamin Supplementation to Pregnant Women (clinicaltrials.gov) - Nov 24, 2014
P4, N=1370, Completed, Sponsor: The Hospital for Sick Children
- Enrollment open, Trial initiation date, Trial primary completion date: Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation (clinicaltrials.gov) - Nov 24, 2014
P2, N=20, Recruiting, Sponsor: Centre for Addiction and Mental Health
Trial primary completion date: Mar 2015 --> Sep 2015 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: Dec 2014 --> Mar 2015
- Clinical: OLFANOR: Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=100, Recruiting, Sponsor: Lille Catholic University
- |||| doxylamine/pyridoxine / Generic mfg.
Trial primary completion date: Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy (clinicaltrials.gov) - Nov 20, 2014
P3, N=150, Active, not recruiting, Sponsor: The Hospital for Sick Children
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Jul 2014 --> Feb 2015
- | hydromorphone hydrochloride / Generic mfg.
New P4 trial, Surgery: Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery (clinicaltrials.gov) - Nov 20, 2014
P4, N=200, Recruiting, Sponsor: University Health Network, Toronto
- Trial completion, Enrollment change: Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic (clinicaltrials.gov) - Nov 20, 2014
P2, N=55, Completed, Sponsor: The Hospital for Sick Children
Trial primary completion date: Jul 2014 --> Feb 2015 Recruiting --> Completed | N=100 --> 55
- Trial primary completion date: Gut Hormone, Nociceptors, Neurotrophic Factors Expression in Functional Dyspepsia (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=300, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Completed | N=100 --> 55 Trial primary completion date: Jul 2014 --> Jul 2015
- Trial primary completion date: Adaptive Family Treatment for Adolescent Anorexia Nervosa (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- remifentanil / Generic mfg.
Trial completion, Surgery: Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens (clinicaltrials.gov) - Nov 19, 2014
P4, N=130, Completed, Sponsor: Sykehuset Telemark
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Completed
- Trial completion: Study of Treatment for Adolescents With Bulimia Nervosa (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=130, Completed, Sponsor: Stanford University
Recruiting --> Completed Active, not recruiting --> Completed
- | ondansetron / Generic mfg.
Trial completion: Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting (clinicaltrials.gov) - Nov 19, 2014
P2, N=30, Completed, Sponsor: Sunnybrook Health Sciences Centre
Active, not recruiting --> Completed Recruiting --> Completed
- |||| granisetron transdermal (SyB-0701) / Synmosa Biopharma, SymBio Pharma, Abeille Pharma
Trial completion: Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) (clinicaltrials.gov) - Nov 19, 2014
P2, N=189, Completed, Sponsor: SymBio Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Enrollment change, Trial withdrawal: Probiotics in Hospitalized Patients Study (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=0, Withdrawn, Sponsor: South Shore Hospital
Recruiting --> Completed N=600 --> 0 | Not yet recruiting --> Withdrawn
- ||||||| Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Trial completion: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Nov 18, 2014
P3, N=1015, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=600 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- |||||||||| New P3 trial: Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005) (clinicaltrials.gov) - Nov 17, 2014
P3, N=120, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P3 trial: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Nov 14, 2014
P3, N=1200, Recruiting, Sponsor: Ironwood Pharmaceuticals, Inc.
- Trial primary completion date: Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=50, Recruiting, Sponsor: Children's Hospital Boston
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Feb 2015
- mizagliflozin (VGX-3235) / Vogenx
Trial completion, Trial primary completion date: A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation (clinicaltrials.gov) - Nov 13, 2014
P2, N=0, Completed, Sponsor: Kissei Pharmaceutical Co., Ltd.
Trial primary completion date: Dec 2013 --> Feb 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014
- mizagliflozin (VGX-3235) / Vogenx
Trial completion, Trial primary completion date: A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation (clinicaltrials.gov) - Nov 13, 2014
P2, N=0, Completed, Sponsor: Kissei Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014
- Enrollment change, Trial termination, Trial primary completion date: Reletex for Nausea in GERD Patients (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=2, Terminated, Sponsor: Northwestern University
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014 N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Nov 2013; study was terminated by investigator due to low enrollment
- | Bridion (sugammadex) / Merck (MSD)
New P4 trial: Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting. (clinicaltrials.gov) - Nov 11, 2014
P4, N=100, Recruiting, Sponsor: T.C. ORDU ÜNİVERSİTESİ
- ||||| Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Enrollment closed: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (clinicaltrials.gov) - Nov 11, 2014
P3, N=1015, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Nov 2013; study was terminated by investigator due to low enrollment Recruiting --> Active, not recruiting
- ||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Nov 7, 2014
P3, N=450, Completed, Sponsor: Purdue Pharma LP
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=900 --> 450
- ||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Nov 7, 2014
P3, N=455, Completed, Sponsor: Purdue Pharma LP
Active, not recruiting --> Completed | N=900 --> 450 Active, not recruiting --> Completed | N=600 --> 455
- Trial completion: Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=100, Completed, Sponsor: Showa Inan General Hospital
Active, not recruiting --> Completed | N=600 --> 455 Recruiting --> Completed
- mizagliflozin (VGX-3235) / Vogenx
New P2 trial: Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC) (clinicaltrials.gov) - Nov 3, 2014
P2, N=0, Recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
New P2/3 trial: Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) - Oct 31, 2014
P2/3, N=28, Recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Oct 31, 2014
P2, N=240, Recruiting, Sponsor: Forest Laboratories
Recruiting --> Completed Not yet recruiting --> Recruiting
- | fosaprepitant / Generic mfg.
Trial termination: Fosaprepitant (MK-0517, EMEND (clinicaltrials.gov) - Oct 30, 2014
P2, N=111, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Completed --> Terminated; Low enrollment
- Trial primary completion date: Improving Pain Management for Older Adults in the Emergency Department (ED) (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=900, Recruiting, Sponsor: Mount Sinai School of Medicine
Completed --> Terminated; Low enrollment Trial primary completion date: Aug 2014 --> Dec 2014
- dronabinol oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain (clinicaltrials.gov) - Oct 28, 2014
P2, N=36, Completed, Sponsor: Radboud University
Trial primary completion date: Aug 2014 --> Dec 2014 Recruiting --> Completed | N=68 --> 36 | Trial primary completion date: Oct 2013 --> Jun 2014
- dronabinol oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain (clinicaltrials.gov) - Oct 28, 2014
P2, N=29, Completed, Sponsor: Radboud University
Recruiting --> Completed | N=68 --> 36 | Trial primary completion date: Oct 2013 --> Jun 2014 Recruiting --> Completed | N=68 --> 29 | Trial primary completion date: Oct 2013 --> Jun 2014
- || relamorelin (RM-131) / AbbVie
P2 data, Trial primary completion date: MOVE-PD: A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation (clinicaltrials.gov) - Oct 24, 2014
P2, N=56, Recruiting, Sponsor: Rhythm Pharmaceuticals, Inc.
Recruiting --> Completed | N=68 --> 29 | Trial primary completion date: Oct 2013 --> Jun 2014 Trial primary completion date: May 2014 --> Mar 2015
- | relamorelin (RM-131) / AbbVie
Trial completion, P2 data: Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation (clinicaltrials.gov) - Oct 24, 2014
P2, N=48, Completed, Sponsor: Rhythm Pharmaceuticals, Inc.
Trial primary completion date: May 2014 --> Mar 2015 Active, not recruiting --> Completed
- | bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial termination: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Oct 24, 2014
P3, N=1407, Terminated, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Terminated; A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met
- relamorelin (RM-131) / AbbVie
Enrollment open: Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation (clinicaltrials.gov) - Oct 24, 2014
P1, N=18, Recruiting, Sponsor: Rhythm Pharmaceuticals, Inc.
Active, not recruiting --> Terminated; A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met Active, not recruiting --> Recruiting
- ||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New P2 trial: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (clinicaltrials.gov) - Oct 22, 2014
P2, N=240, Not yet recruiting, Sponsor: Forest Laboratories
- Enrollment open: The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia (clinicaltrials.gov) - Oct 20, 2014
P4, N=460, Recruiting, Sponsor: Osaka City University
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion: Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=79, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Trial primary completion date: Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=100, Recruiting, Sponsor: Showa Inan General Hospital
Not yet recruiting --> Completed Trial primary completion date: Apr 2014 --> Oct 2014
- Trial primary completion date, HEOR: Medico-economic Evaluation of ENTERRA Therapy (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=220, Active, not recruiting, Sponsor: University Hospital, Rouen
Trial primary completion date: Apr 2014 --> Oct 2014 Trial primary completion date: Jul 2014 --> Oct 2014
- Enrollment open: Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation. (clinicaltrials.gov) - Oct 17, 2014
P2, N=228, Recruiting, Sponsor: Danisco Sweeteners Oy
Trial primary completion date: Jul 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion, Head-to-Head: A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy (clinicaltrials.gov) - Oct 17, 2014
P3, N=270, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
Enrollment change: Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118 (clinicaltrials.gov) - Oct 17, 2014
P1, N=214, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=46 --> 214
- ||||||| Emestop (ramosetron hydrochloride) / Samyang Group
Trial completion: A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (clinicaltrials.gov) - Oct 17, 2014
P3, N=151, Completed, Sponsor: Astellas Pharma Inc
N=46 --> 214 Active, not recruiting --> Completed
- ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg., palonosetron intravenous / Generic mfg.
Trial primary completion date: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=85, Recruiting, Sponsor: Northside Hospital, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- Enrollment open: Fibers and Gut Health (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=120, Recruiting, Sponsor: Nestl
Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- Trial completion, Enrollment change: Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=47, Completed, Sponsor: Michael Lowe
Not yet recruiting --> Recruiting Recruiting --> Completed | N=70 --> 47
- || Trial primary completion date, Surgery: MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=150, Recruiting, Sponsor: Duke University
Recruiting --> Completed | N=70 --> 47 Trial primary completion date: Oct 2014 --> Mar 2015